Article Abstract

Role of fibroblast growth factor receptor in sunitinib-resistant renal cell carcinoma

Authors: Ninadh Malrina D’Costa, Claudia Chavez-Munoz, Alan I. So

Abstract

In renal cell carcinoma (RCC), surgical therapy remains to be the only curative approach for patients with localised kidney tumor, with recurrence rates as high as 40% in high risk patients. As well, even though there are now many approved therapies for metastatic RCC (mRCC), resistance eventually develops and is fatal for metastatic patients. Tyrosine kinase inhibitors (TKIs) that target the VEGF pathway are considered first-line therapy for clear cell RCC, the most common type of RCC.